Insulin-Like Growth Factors and Their Binding Proteins in Tumors and Ascites of Ovarian Cancer Patients: Association With Response To Neoadjuvant Chemotherapy

Natalia V Yunusova1,2*, Alisa B Villert1, Liudmila V Spirina1,2, Alena E Frolova1, Larisa A Kolomiets1,2, Irina V Kondakova1

Abstract

Purpose: Tumor cell growth and sensitivity to chemotherapy depend on many factors, among which insulin-like growth factors (IGFs) may play important roles. The aim of the present study was to evaluate the levels of insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) in primary tumors and ascites as predictors of response to neoadjuvant chemotherapy in ovarian cancer (OC) patients. Materials and Methods: Tumor tissue samples and ascitic fluid were obtained from 59 patients with advanced OC. The levels of IGF-I, IGF-II, IGFBP-3, IGFBP-4 and PAPP-A were determined using ELISA kits. Taking into account the data on expression of these IGF-related proteins and outcome, logistic regression was performed to identify predictors of response to neoadjuvant chemotherapy. Results: Human ovarian tumors expressed IGFs, IGFBP-3, IGFBP-4 and PAPP-A and these proteins were also present in ascites fluid and associated with its volume. IGFs and IGFBPs in ascites and soluble PAPP-A might play a key role in ovarian cancer progression. However, levels of proteins of the IGF system in tumors were not significant predictors of objective clinical response (oCR). Univariate analysis showed that the level of IGF-I in ascites was the only independent predictor for oCR. Conclusion: The level of IGF-I in ascites was shown to be an independent predictor of objective clinical response to chemotherapy for OC patients treated with neoadjuvant chemotherapy and debulking surgery.

Keywords: Insulin-like growth factors- insulin-like growth factor binding proteins- ovarian cancer- ascites

Asian Pac J Cancer Prev, 17 (12), 5315-5320

Introduction

Tumor cell growth and sensitivity to chemotherapy depend on many factors, among which insulin-like growth factors (IGFs) play an important role. The IGF system includes IGF-I, IGF-II, their receptors (IGF-IR and IGF-II/mannose-6-phosphate receptor) and six IGF binding proteins (IGFBPs) (Firth and Baxter, 2002; Samani et al., 2007; Yunusova et al., 2016). Many proteases are involved in the regulation of IGFBPs. Among them, pregnancy-associated plasma protein (PAPP-A) is a metalloprotease involved in the hydrolysis of IGFBP-4 and IGFBP-5 (Yunusova et al., 2013; Thomsen et al., 2015). Upon binding of IGFs to IGF-IR, many signaling pathways can be activated, leading to stimulation of cell proliferation, motility and inhibition of apoptosis (Yunusova et al., 2015).

Ovarian cancer metastasis to the greater omentum and ascitic fluid accumulation in the peritoneal cavity indicate the disease progression. Malignant ascites constitute a tumor microenvironment promoting migration, survival and enhanced invasive activity of tumor cells due to significant amounts of growth factors, cytokines and fibronectin in ascites of ovarian cancer patients (Sodek et al., 2012; Latifi et al., 2012). The levels of IGFs and IGFBPs in ascites were similar or lower than those in serum. However, PAPP-A proteolytic activity was significantly higher in malignant ascites than in serum. Ascites was more potent than serum in activating the IGF-IR receptor in vitro (KIRA assay) (Thomsen et al., 2015).

The ability to perform optimal cytoreduction is currently regarded as the most important prognostic factor for patients with advanced ovarian cancer (Morimoto et al., 2016). In the absence of conditions for optimal primary cytoreductive surgery in patients with advanced ovarian cancer, neoadjuvant chemotherapy (NACT) may be administered. When compared with primary cytoreductive surgery, NACT is associated with a greater percentage of optimal cytoreduction, less blood loss and better quality of life (Weinberg et al., 2010). Chemoresistance in ovarian cancer cells may be associated with the overexpression of proteins of the IGF system or components of the IGF-mediated signaling pathway. Overexpression of IGF-IR and phosphatidylinositol 3-kinase were associated with platinum resistance of ovarian cancer cells (Eckstein...
et al., 2009). The ovarian cancer cell lines, resistant to taxanes, had a high level of IGF-II, and the decrease in the level of IGF-II restored the cells’ sensitivity to taxanes (Huang et al., 2010). L.Lu et al. (2006) showed no association between the IGF-II and IGFBP-3 mRNA expression in tumors and response to platinum-based chemotherapy (Lu et al., 2006). It has been recently demonstrated that ascites is a platform for translational research in ovarian cancer. The accessibility of ascitic fluid and its cellular components make it an excellent source of tumor cells for the investigation of prognostic and predictive biomarkers, as well as for molecular profiling analysis (Sodek et al., 2012; Latifi et al., 2012). The elevated level of IGFBP-3 before chemotherapy and the high level of IGF-II after chemotherapy in ascites of ovarian cancer patients were shown to correlate with low overall survival, and the level of IGF-II after chemotherapy was an independent prognostic factor in Cox multivariate analysis (Slipicevic et al., 2009). Thus, no strong association between the response to chemotherapy using the ovarian cancer cell lines and the response to chemotherapy in human ovarian cancer was found (translational studies). The aim of this study was to evaluate protein levels of the IGF system in the primary tumor and ascites of ovarian cancer patients and to identify the predictors of response to NACT.

Materials and Methods

Patients. The study was approved by the Local Ethics Committee of the Cancer Research Institute of Tomsk National Research Medical Center. All patients provided informed written consent before being included in this study. Tissue samples of primary tumors and ascites were obtained from 59 patients with IIIC-IV stages of ovarian cancer (FIGO, 2013). Patients with stage IB and IC ovarian cancer constituted a comparison group. All patients with early ovarian cancer underwent radical surgery. Between 2012 and 2015, the patients were treated at the Department of Gynecology of the Cancer Research Institute of Tomsk National Research Medical Center. They were Caucasian and resided in the Western Siberia region. All ovarian cancer patients underwent diagnostic laparoscopy for morphological verification and surgical staging as well as for sampling of tumor tissue and ascites. Histological sections were prepared from paraffin blocks according to the standard method with the staining with hematoxylin-eosin. In our study, all ovarian cancers were characterized as high-grade serous adenocarcinomas. R. V. Verhaak et al. (2013) in their multicenter study reported that up to 80% of all malignant epithelial ovarian tumors were high-grade serous adenocarcinomas (Verhaak et al. (2013). All patients were tested for the presence of BRCA1 mutations inC 5382 by allele-specific PCR in real time. Patients included in this study were BRCA1-negative. The volume of ascites was measured clinically and by ultrasound examination using the LOGIQ S6 machine. In accordance with the recommendations of T. Feidenberg et al. (2014), the patients were divided into 3 subgroups: patients having low-volume (<200 mL), moderate-volume (200-1,000 mL) and high-volume ascites (≥ 1,000 mL) (Feidenberg et al., 2014). All 59 patients with advanced ovarian cancer met the recommendations for ASCO and SGO Release Clinical Practice Guideline on Neoadjuvant Therapy for Newly Diagnosed Advanced Ovarian Cancer (2016). The NACT regimen was administered as follows: carboplatin plus paclitaxel, 175mg/ m², carboplatin AUC 6 on day 1, every 21 days, 3-4 courses. Clinical response to treatment was determined after 3-4 cycles by RECIST criteria (2009), according to which the result was regarded as an objective clinical response (oCR) in patients with partial or complete response, while patients who had a stable disease or disease progression were non-responders. Pathological complete response was defined as no residual tumor in abdominal cavity and lymph nodes. The Gynaecologic Oncology Group (GOG) currently defines optimal cytoreduction as leaving residual disease less than 1 cm in maximum tumor diameter.

Serum CA125 and HE4 assay. CA-125 and HE4 were used for monitoring epithelial ovarian cancer (Wang et al., 2013, Steffensen et al., 2016; Feng et al., 2016), therefore, we measured CA-125 and HE4 serum levels before NACT and analyzed with oCR. We used ELISA kits developed by Fujirebio Diagnostic, Inc (Sweden).

Ascites supernatants and cleared tissue homogenate preparation. Tumor samples (100 mg) were homogenized and then resuspended in 300 μL of 50 mM Tris-HCl buffer (pH 7.5) containing 2 mM ATP, 5 mM MgCl2, 1 mM dithiothreitol, 1 mM EDTA, and 100 mM NaCl. The homogenate was centrifuged at 100,009g for 60 min at 4°C as previously described (Spirina et al., 2012). For preparation of supernatant aliquots of ascites (about 10 mL) was centrifuged at 4°C and 900 g for 20 minutes. The supernatants of the ascites were collected, frozen and stored at -200°C prior to the studies. For the preparation of clarified homogenates, tumor tissue (approximately 100 mg) was homogenized in liquid nitrogen, then resuspended in 300 300 μL of 50 mM tris-HCl-buffer (pH 7.5). The homogenate was centrifuged for 60 min at 10000 g and 4°C.

ELISA. The levels of IGF-I, IGF-II, IGFBP-3, IGFBP-4 and PAPP-A were evaluated in the clarified tumor homogenates and ascites supernatants using the ELISA kits (R&D Systems, Mediagnost, Abcam) in Anthos 2020 microplate reader. The protein concentration in homogenates and supernatants was determined by Lowry.

Flow cytometry. Preparing cell suspension. Samples of ovarian cancer tissues were disintegrated on Becton Dickinson (BD) Medimashine System using BD “Cell Wash” buffer. Cell suspension was filtrated through a 50 μm Syringe Filcons nylon filter. This procedure is optimal for cell suspensions from tissues due to the absence of their contamination. Number of cells was counted in BD Trucount tubes (BD, USA) by flow cytometry. Flow cytometry. Extracellular staining was performed with CD221 (IGR-IR) phycoerythrin (PE) antibody (BD). For intracellular staining, cells were fixed and permeabilized using Cytofix/Cytoperm kit (BD, USA) (standard protocol). Aliquots of cell suspensions were incubated with conjugated antibodies at 200 C for 30 minutes. We used anti-cytokeratin 18 fluorescein isothiocyanate as a primary antibody (FITC) (BD, Santa Cruz). Results were
The levels of IGFs, IGFBPs, and PAPP-A were then investigated in ascitic fluid in relation to the ascites volume (Table 3). Patients with high-volume ascites had decreased IGF-II level. The level of PAPP-A metalloproteinase was significantly higher in patients with moderate- and high-volume ascites compared to that observed in patients with low-volume ascites (p < 0.05).

Taking into account the data on the expression of the IGF-related proteins associated with ovarian cancer chemoresistance to identify predictors of response to NACT, the logistic regression analysis was performed. A total of 40 patients had achieved oCR, and 19 patients were non-responders. Only 4 patients (6.7%) had pathological complete response. Thirty patients (51%) had optimal and twenty-nine (49%) had suboptimal cytoreduction.

We analyzed not only clinical characteristics (patients’ age, FIGO stage and ascites volume) but also the levels of CA125 and HE4 as well as the levels of proteins of the IGF system in tumor tissue and ascites before NACT. The association between these parameters and oCR is shown in Table 4. The levels of proteins of the IGF system in tumor were not significant predictors of oCR. The univariate analysis showed that the level of IGF-I in ascites was the only independent predictor for cOR (Table 4).

### Results

The IGFs and IGFBPs levels were 10 times higher in ascites than in tumor tissue. There was no significant difference in the concentration of PAPP-A between primary tumor and ascites (Table 1). The level of IGF-II was significantly higher and the level of IGFBP-3 was significantly lower in patients with advanced ovarian cancer than in patients with early ovarian cancer (p<0.05). However, the expression of tyrosine kinase receptor IGF-IR was higher in early than in advanced cancer samples (91.6% (89.0-96.0) versus 79.6% (68.0-90.0) of cytokeratin-18 positive tumor cells, p <0.05).

Multiple correlations were revealed between IGFs and IGFBPs levels in ascites and between IGFs and IGFBPs in tumors (Table 2). There was no correlation between IGF-IR expression and IGFs/IGFBPs levels in tumors.

### Discussion

In our study, the high levels of IGFs and IGFBPs in a cell-free compartment of ascites were mainly analyzed using the FACS Diva 6.1 software. Percentage of cells specifically stained for IGF-IR was analyzed (%).

Statistical analyses. Statistical analysis was performed using Statistica 10.0 software. All data were expressed as medians with interquartile ranges or as means with standard errors. To evaluate the difference, either Mann-Whitney or Kruskal-Wallis test was used. Correlation analysis on data was carried out with Spearman Rank Correlation test. P-values < 0.05 were considered statistically significant. Univariate logistic regression analysis was performed to predict oCR.

### Table 1. IGFs, IGFBPs and PAPP-A Level (ng/mg of Protein) in Primary Tumor and Ascites in Patients with Early and Advanced Ovarian Cancer, Me (25-75%)

| Parameters | IGF-I | IGF-II | IGFBP-3 | IGFBP-4 | PAPP-A |
|------------|------|-------|--------|--------|--------|
| Primary tumor (IB,C Stage), n=15 | 0.1 (0.1-0.4) | 3.4 (2.0-3.6) | 17.9 (16.2-24.4) | 6.0 (3.6-12.4) | 0.4 (0.01-0.4) |
| Primary tumor (IIIC-IV Stage), n=59 | 0.1 (0.060-0.305) | 5.6 (3.28-8.49) | 5.9 (0.90-8.10) | 3.6 (0.6-5.6) | 0.3 (0.09-0.32) |
| Ascites (IIIC-IV Stage), n=53 | 2.5 (0.9-2.7) | 115.0 (89.0-183.0) | 190.0 (140.0-266.0) | 62.3 (51.4-77.8) | 0.2 (0.05-0.42) |

Note, 1,2 – changes between protein levels in tumor samples in early and advanced ovarian cancer; 2,3 – changes between protein levels in primary tumor and ascites

### Table 2. Spearman Rank Order Correlations between Concentrations of IGF Related Peptides in Tumors and Ascites

|                 | IGF-I | IGF-II | IGFBP-3 | IGFBP-4 | PAPP-A |
|-----------------|------|-------|--------|--------|--------|
| IGF-I tumor     | 0.4  | 0.4   | 0.7    | -0.4   | 0.6    |
| IGF-II tumor    | -0.5 |       |        |        |        |
| IGFBP-3 tumor   | 0.4  | -0.5  | 0.4    | 0.6    | -0.5   |
| IGFBP-4 tumor   | 0.4  | 0.4   | 0.3    | 0.7    | -0.7   | 0.6    |
| PAPP-Atumor     | 0.7  | 0.6   | 0.7    | 0.7    | 0.8    |
| IGF-lascites    | -0.4 | -0.5  | -0.7   |        |        |
| IGF-Iascites    | 0.6  | 0.5   | 0.5    | 0.8    | 0.8    |
| IGFBP-3ascites  | 0.6  | 0.5   |        |        |        |
| IGFBP-4ascites  | 0.4  |      |        |        |        |
| PAPP-A ascites  | -0.5 |      |        |        |        |

Notes, Only P-values below 0.05 are listed; All measurements were performed in tumor and ascites; Each correlation is based on 50 paired observations.
associated with peritoneal ovarian cancer metastasis. Most authors reported that the elevated levels of total protein and growth factors in ascites were related with their increased secretion of both primary tumor cells and tumor/non-tumor cells floating in ascites (Sodek et al., 2012; Latifi et al., 2012). High levels of growth factors in ascites were explained by the increased peritoneal capillary permeability due to excessive production of vascular endothelial growth factor by these cells, thereby promoting the release of growth factors from ascites.

Table 3. IGFs, IGFBPs and PAPP-A Level (ng/mg of Protein) in Ascites in Patients with Advanced Ovarian Cancer in Ascites Depending on Its Volume, Me (25-75%)

| Ascites volume (mL)                  | IGF-I       | IGF-II      | IGFBP-3      | IGFBP-4      | PAPP-A      |
|-------------------------------------|-------------|-------------|--------------|--------------|-------------|
| Low volume (less 200 mL), n=10      | 1.9 (1.7-2.3) | 193.0 (55.0-378.0) | 96.9 (88.2-166.0) | 5.9 (3.6-12.4) | 0.04 (0.0-0.12) |
| Moderate volume, n=10               | 3.9 (0.5-9.5) | 165.0 (84.0-281.0) | 268.0 (100.0-404.0) | 3.6 (0.6-5.6) | 0.4 (0.13-0.5) |
| High volume, n=33                   | 3.0 (1.3-5.0) | 67.3 (28.7-124) | 210.0 (140.0-266.0) | 62.3 (51.4-77.8) | 0.3 (0.14-0.5) |

Note, 1,2 , changes between protein levels in low- and moderate-volume ascites samples; 1,3 , changes between protein levels in low- and high-volume ascites samples; 2,3, changes between protein levels in moderate- and high-volume ascites samples

Table 4. Univariate Analysis to Predict Objective Clinical Response

| Clinicopathological characteristics | Univariate analysis |
|-------------------------------------|---------------------|
|                                     | Odds ratio | 95%CI | P value |
| Age (years):                        |            |      |         |
| ≤50, n=24                           | 1          |      |         |
| >50, n=35                           | 1.1        | 0.4-3.3 | 0.86 |
| FIGO stage:                         |            |      |         |
| IIC, n=47                           | 1          |      |         |
| IV, n=12                            | 1.1        | 0.3-4.2 | 0.92 |
| Ascites (ml):                       |            |      |         |
| ≤1000, n=20                         | 1          |      |         |
| >1000, n=33                         | 0.5        | 0.1-1.7 | 0.19 |
| CA125 level before NACT (IU/ml)     |            |      |         |
| <500, n=27                          | 1          |      |         |
| ≥500, n=30                          | 0.7        | 0.2-2.0 | 0.50 |
| HE4 level before NACT (pmol)        |            |      |         |
| <500, n=29                          | 1          |      |         |
| ≥500, n=30                          | 0.5        | 0.2-1.7 | 0.16 |
| Level of proteins of IGF-system in ascites before NACT (ng/mg of protein) | | | |
| IGF-I                               |            |      |         |
| ≥2.48, n=26                         | 1          |      |         |
| <2.48, n=27                         | 3.7        | 1.0-6.7 | 0.048 |
| IGF-II                              |            |      |         |
| <115, n=26                          | 1          |      |         |
| ≥115, n=27                          | 1.6        | 0.4-4.8 | 0.48 |
| IGFBP-3                             |            |      |         |
| <190, n=26                          | 1          |      |         |
| ≥190, n=27                          | 1.9        | 0.5-5.0 | 0.32 |
| IGFBP-4                             |            |      |         |
| <97.0, n=27                         | 1          |      |         |
| ≥97.0, n=26                         | 0.9        | 0.4-2.4 | 0.57 |
| PAPP-A                              |            |      |         |
| Absent, n=23                        | 1          |      |         |
| Present, n=30                       | 0.6        | 0.3-1.9 | 0.44 |
the capillaries into the peritoneal cavity (Staldmann et al., 2005). Our data, indicating the multiple relationships between the levels of IGFs in ascites and the levels of IGFs and IGFBPs in tumor, confirmed this hypothesis. We revealed that the IGF-II level was 10 times higher than the IGF-I level in both tumor tissue and tumor ascites. A similar trend in malignant ascites was previously shown (Thomsen et al., 2015). The difference in the IGF-II/IGF-I ratio in our study and in the study of Thomsen J. et al. may be due to different study design. Our findings in measuring the IGF-II/IGF-I ratio were not completely consistent with those reported by Thomsen J. et al. (2015). In their study, the concentration of IGF-related peptides in ascites was expressed as micrograms per liter of ascitic fluid. In our study, as the protein concentration in ascites varied from 10 to 26 mg per mL, the concentrations of IGFs, IGFBPs and PAPP-A in ascites were calculated as the amount of protein per ascites.

We revealed the relationship between the levels of IGF-II and PAPP-A and the volume of ascites. The high level of PAPP-A metalloproteinase in ascites was associated with the high-volume ascites. Bold H.B. et al. (2011) showed that the enhanced cellular proliferation, increased vascularization and cellular invasion into Matrigel occurred in ovarian cancer cell line with a high PAPP-A expression compared to that with a low PAPP-A expression. We previously found higher expression of PAPP-A in peritoneal metastases of ovarian cancer as compared to that in the primary tumor (Yunusova et al., 2015). Although the PAPP-A levels in tumors and ascites were not associated with oCR in advanced ovarian cancer, further studies are needed to evaluate cellular and extracellular forms of PAPP-A in order to clarify the role of this protease in the ovarian cancer metastasis, chemoresistance and progression. Data on different molecular profiles of high-grade serous carcinomas with low- (200 mL) and high- (more than 1,000 mL) volume ascites showed that differences were mainly related to the expression of genes and proteins associated with regulation of immune response. For high-grade serous ovarian cancer, the presence of large-volume ascites was associated with low rates of optimal cytoreduction and overall survival. Better surgical outcome and longer overall survival were observed in patients with low-volume ascites (less 200 mL) (Feidenberg et al., 2014). In our study, the ascites volume was not associated with response to NACT. There was an insignificant tendency towards a decrease in the rate of oCR in patients with high-volume ascites (Table 4). Published reports on the prognostic significance of ascites volume in ovarian cancer are often contradictory. In the study of Angioli R. et al. (2013), ascites volume of less than 500 mL combined with preoperative serum HE4 level of less than 262 pmol/L were able to target candidates with the potential for optimal cytoreduction (all histotypes of advanced ovarian cancer). Feigenberg T. et al. (2014), demonstrated better surgical outcome and prolonged overall survival for the low-volume ascites group compared to the high-volume ascites group. However, the prognostic value of the ascites volume appeared to be limited by the existence of a large group of patients with moderate volume of ascites.

Until now, there are only a few clinical (volume of ascitic fluid, FDG-PET metabolic response), laboratory (CA125 and HE4 levels) and molecular (survivin expression, IGF-II and IGFBP-3 levels in ascites) parameters that can be used as predictive or prognostic markers in ovarian cancer patients treated with NACT and debulking surgery. Among them, there are no strong predictors of oCR (Avril et al., 2005; Slipcevic et al., 2009; Angioli et al., 2013; Gasowska-Bodnar et al., 2014; Morimoto et al., 2016). Our results were consistent with several recent reports demonstrating a 4-10-fold increase in the concentration of IGF-II in ascites as compared to that of IGF-I, thus indicating that IGF-II can contribute significantly to IGF-IR activation. On the other hand, IGF-II only has an IGF-IR cross-reactivity of 12% relative to IGF-I. Hence, it is reasonable to assume that the majority of the signal obtained by the bioassay originates from IGF-I (Chen et al., 2003; Thomsen et al., 2015). Further investigations for evaluating the function and bioavailability of IGF-I in ascites are need to clarify the role of IGF-I as a biomarker in ovarian cancer.

Conclusion. The IGFs and IGFBPs levels were 10 times higher in ascites than in tumor tissue. There was no significant difference in the concentration of PAPP-A between primary tumor and ascites. We were the first to show the relationship between the levels of IGF-II and PAPP-A and the volume of ascites. The univariate analysis showed that the level of total IGF-I in ascites was an independent predictor of oCR to chemotherapy for OC patients treated with neoadjuvant chemotherapy and debulking surgery.

Acknowledgments

The study was supported by long-term target program “Urgent measures for improving cancer care among the population of the Tomsk region for 2011-2013”.

Abbreviations

IGF-I and IGF-II - insulin-like growth factors, IGFBPs - IGF binding proteins, IGF-IR - insulin-like growth factor receptor I type, PAPP-A - pregnancy-associated plasma protein A, cOR – objective clinical response.

References

Angioli R, Plotti F, Capriglione S, et al (2013). Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?. Gynecol Oncol, 128, 579-83.

Avril N, Sassen S, Schmalfeldt B, et al (2005). Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol, 23, 7445-53.

Bold HB, Conover CA (2011). Overexpression of pregnancy-associated plasma protein-A in ovarian cancer. Endocrinology, 152, 1470-8.

Chen JW, Ledet T, Orskov H, et al (2003). A high sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab, 284, 7445-53.
Eckstein N, Servan K, Hildebrandt B, et al (2009). Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. *Cancer Res*, 69, 29996-3003.

Feigenberg T, Clarke B, Virtanen C, et al (2014). Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. *Biomed Res Int*, 367103. doi: 10.1155/2014/367103.

Feng Z, Wen H, Bi R, et al (2016). Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients, *BMC Cancer*, 16, 43.

Firth SM, Baxter RC (2002). Cellular actions of the insulin-like growth factor binding proteins. *Endocr Rev*, 23, 824-54.

Gasowska-Bodnar A, Bodnar L, Dąbek A, et al (2014). Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy. *Int J Gynecol Cancer*, 24, 687-96.

Huang GS, Brouwer-Visser J, Ramirez MJ, et al (2010). Insulin-like growth factor 2 expression modulates taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. *Clin Cancer Res*, 16, 2999-3010.

Morimoto A, Nagao S, Kogiku A, et al (2016). A preoperative low cancer antigen 125 level (<25.8 mg/dL) is useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer. *Jpn J Clin Oncol*, 46, 517-21.

Samani AA, Yakar S, LeRoith D, Brodt P (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insight. *Endocr Rev*, 28, 20-47.

Slipicevic A, Øy GF, Askildt IC, et al (2009). Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. *Hum Pathol*, 40, 527-37.

Spirina LV, Bochkareva NV, Kondakova IV, et al (2012). Regulation of insulin-like growth NF-kB proteasome system in endometrial cancer. *Mol Biol (Mosk)*, 46, 452-60.

Sodek KL, Murphy KJ, Brown TJ, Rinquette MJ (2012). Cell-cell and cell–matrix dynamics in intraperitoneal cancer metastasis. *Cancer Metastasis Rev*, 31, 397-414.

Stadlmann S, Amberger A, Pollheimer J, et al (2005). Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. *Gynecol Oncol*, 97, 784-9.

Thomsen J, Hjortebjerg R, Espelund U, et al (2015). PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma. *Oncotarget*, 6, 32266-78.

Verhaak RG, Tamayo P, Yang YJ, et al (2013). Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. *J Clin Invest*, 123, 517-25.

Wang F, Ye Y, Xu X, et al (2013). CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. *J Ovarian Res*, 6, 14.

Weinberg LE, Rodriguez G, Hurteau JA, et al (2010). The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. *J Surg Oncol*, 101, 334-43.

Yunusova NV, Spirina LV, Kondakova IV, et al. (2013). The relationship of metalloproteinase PAPP-A expression with the expression of growth and transcriptional factors in endometrial cancer. *Biol Bull*, 40, 253-9.

Yunusova NV, Kondakova IV, Kolomiets LA, et al (2015). The insulin-like growth factors system in ovarian cancer metastasis: the relation with p45 Ser β-catenin. *Molekulyrnaya Meditsina*, 4, 17-22. [in Russian].

Yunusova NV, Spirina LV, Frolova AE, et al (2016). Association of IGFBP-6 expression with metabolic syndrome and with adiponectin and IGF-IR receptor levels in colorectal cancer. *Asian Pac J Cancer Prev*, 17, 3963-9.